State Of Wyoming Ligand Pharmaceuticals Inc Transaction History

State Of Wyoming

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$49.57 - $72.63 $63,846 - $93,547	1,288 New	1,288 $91,000
Q1 2023 May 12, 2023	BUY	$65.67 - $77.08 $124,641 - $146,297	1,898 Added 284.13%	2,566 $188,000
Q4 2022 Feb 14, 2023	BUY	$61.72 - $96.74 $41,228 - $64,622	668 New	668 $44,000
Q2 2022 Aug 15, 2022	SELL	$74.52 - $117.06 $18,480 - $29,030	-248 Reduced 68.51%	114 $10,000
Q1 2022 May 13, 2022	SELL	$94.99 - $151.56 $17,098 - $27,280	-180 Reduced 33.21%	362 $41,000
Q4 2021 Feb 11, 2022	BUY	$127.69 - $165.85 $22,984 - $29,853	180 Added 49.72%	542 $84,000
Q3 2021 Feb 11, 2022	BUY	$102.33 - $144.73 $25,889 - $36,616	253 Added 232.11%	362 $50,000
Q2 2021 Feb 11, 2022	BUY	$113.03 - $155.64 $12,320 - $16,964	109 New	109 $14,000

257

18.2M

26.8K

9.3K

Ticker LGND
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 16,882,800
Market Cap $2.02B
Description
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Veklury for the treatment of moderate or severe COVID-19;...

Get notified when there are updates to the investment portfolio of State Of Wyoming, based on Form 13F filings with the SEC.

Stay updated on State Of Wyoming with notifications on news.